Takeda and CSL Behring have set up an alliance with Biotest, Bio Products Laboratory, Octapharma and LFB. The group will work on a treatment made from the plasma of patients who have recovered from COVID-19.

Known as hyperimmune immunoglobulins, these drugs are made by purifying antibodies from donated plasma. Takeda had been working on TAK-888, a polyclonal hyperimmune globulin (H-IG) against SARS-CoV-2, the virus that causes COVID-19, but the partners will now focus their efforts on a single, unbranded medicine. Source: Fierce Biotech 9/4/2020